Axxcess Wealth Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.04M Sell
9,553
-18
-0.2% -$1.86K 0.02% 521
2026
Q1
$994K Sell
9,571
-314
-3% -$33.5K 0.03% 241
2025
Q4
$1.02M Buy
9,885
+841
+9% +$81.8K 0.02% 508
2025
Q3
$817K Sell
9,044
-70
-0.8% -$6.13K 0.02% 493
2025
Q2
$802K Buy
9,114
+416
+5% +$36.1K 0.02% 482
2025
Q1
$793K Buy
8,698
+3,985
+85% +$359K 0.02% 447
2024
Q4
$407K Sell
4,713
-4,974
-51% -$450K 0.01% 595
2024
Q3
$921K Sell
9,687
-356
-4% -$33.8K 0.02% 404
2024
Q2
$919K Sell
10,043
-196
-2% -$17.5K 0.02% 389
2024
Q1
$929K Sell
10,239
-1,394
-12% -$122K 0.03% 388
2023
Q4
$947K Sell
11,633
-506
-4% -$39.7K 0.03% 370
2023
Q3
$969K Hold
12,139
0.03% 326
2023
Q2
$956K Buy
12,139
+161
+1% +$12.6K 0.07% 237
2023
Q1
$930K Buy
11,978
+8
+0.1% +$617 0.07% 245
2022
Q4
$931K Hold
11,970
0.08% 235
2022
Q3
$805K Sell
11,970
-420
-3% -$30.9K 0.08% 222
2022
Q2
$952K Hold
12,390
0.09% 194
2022
Q1
$988K Hold
12,390
0.08% 215
2021
Q4
$954K Buy
+12,390
New +$921K 0.07% 218

Other funds holding PPH

Axxcess Wealth Management's PPH Position: Q2 2026 in Review

Axxcess Wealth Management reduced its VanEck Pharmaceutical ETF (PPH) stake by 0.19% in Q2 2026, selling an estimated $1.86K and leaving 9,553 shares worth $1.04M. The position accounts for 0.02% of the portfolio, ranked #521.

Axxcess Wealth Management first reported a position in PPH in Q4 2021 and has held it in 19 quarters since. 47 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

  • Axxcess Wealth Management held 9,553 shares of VanEck Pharmaceutical ETF worth $1.04M as of Q2 2026.
  • Axxcess Wealth Management sold 18 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $1.86K.
  • VanEck Pharmaceutical ETF made up 0.02% of Axxcess Wealth Management's portfolio in Q2 2026, its #521 holding.
  • Axxcess Wealth Management first reported a position in VanEck Pharmaceutical ETF in Q4 2021 and has held it in 19 quarters since.
  • 47 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Axxcess Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.